Mumbai, Maharashtra, India, May 2026 – Apothecon Pharmaceuticals Pvt. Ltd. has appointed Shyamakant Giri as its Group Chief Executive Officer, reinforcing the company’s strategic focus on global expansion, complex chemistry, high-potency APIs, and innovation-led pharmaceutical growth.
A seasoned pharmaceutical and healthcare leader with more than two decades of industry experience, Shyamakant Giri brings deep expertise across global operations, diagnostics, biologics, injectable manufacturing, hospital business, CDMO growth, and international market expansion spanning India, Africa, CIS, LATAM, Gulf, and Southeast Asian markets.
In his new role at Apothecon Pharmaceuticals Pvt. Ltd., he will lead the vertically integrated operations of the Apothecon Group, including India-based Apothecon Pharmaceuticals and US-based Navinta, with a strategic focus on scaling research-led capabilities, strengthening manufacturing excellence, and expanding the company’s global pharmaceutical footprint.
Prior to joining Apothecon Pharmaceuticals Pvt. Ltd., Shyamakant Giri served as Chief Executive Officer at Gland Pharma Limited, where he spearheaded operations across India and Europe, managing a $650 million P&L, 11 manufacturing facilities, and a workforce of over 5,000 employees. During his tenure, he drove strategic initiatives to strengthen the company’s injectable and biologics CDMO positioning in global markets.
Earlier, he worked with Amneal Pharmaceuticals as Managing Director & President, leading commercial expansion across India, Africa, Gulf, CIS, LATAM, China, and South Asian markets. He played a pivotal role in establishing the company’s presence across ROW markets through distributor expansion and multiple business verticals in India.
Before that, Shyamakant Giri served as Chief Executive Officer at Rivaara Labs, where he led the organization during a critical growth phase, overseeing molecular diagnostics expansion, pathology business launches, manufacturing acquisitions, proprietary point-of-care device introductions, and strategic healthcare innovation initiatives during the COVID period.
A significant part of his leadership journey was with Abbott, where he spent over 17 years across multiple leadership roles including General Manager & Country Head – India Region & Africa, Director – EPD Hospital Business, Country Manager – AbbVie Business India Region, Business Unit Director, and Head – Hospital Care. During this period, he led diagnostics, institutional healthcare, government business, hospital care, and specialty pharmaceutical operations across India and international markets.
He began his pharmaceutical leadership career with Wockhardt, where he held roles including Regional Sales Manager and Product Manager, building early expertise in pharmaceutical commercialization and healthcare business operations.
About Apothecon Pharmaceuticals Pvt. Ltd.
Apothecon Pharmaceuticals Pvt. Ltd. is a research-driven pharmaceutical company established in 2007 and headquartered in Vadodara, India. The company specializes in niche APIs and formulations and serves global pharmaceutical markets through high-quality manufacturing and research-led innovation.
The company operates manufacturing facilities approved by regulatory authorities including the US FDA, UK MHRA, WHO GMP, and State FDCA, while also being audited by international agencies including ANVISA Brazil and Russia. Apothecon Pharmaceuticals supplies products globally with a focus on stringent quality standards, competitive pricing, and specialized pharmaceutical solutions.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
